Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
2 Top Growth Stocks to Buy Right Now and Hold Forever | fool.com • |
Better Dividend Stock: AbbVie or Johnson & Johnson? | fool.com • |
(JNJ) Trading Advice | news.google.com • |
Johnson & Johnson Stock: Buy, Sell, or Hold? | fool.com • |
Johnson & Johnson Stock: Buy, Sell, or Hold? | news.google.com • |
Generational Wealth Builders: 3 Stocks to Own for Decades of Gains | investorplace.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-16 | 2024-03 | 2.64 | 2.71 | 0.07 | 2.65% |
2024-01-23 | 2023-12 | 2.27 | 2.29 | 0.02 | 0.88% |
2023-10-17 | 2023-09 | 2.52 | 2.66 | 0.14 | 5.56% |
2023-07-20 | 2023-06 | 2.61 | 2.8 | 0.19 | 7.28% |
2023-04-18 | 2023-03 | 2.51 | 2.68 | 0.17 | 6.77% |
2023-01-24 | 2022-12 | 2.22 | 2.35 | 0.13 | 5.86% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-17 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-17 | Raymond James | Upgrade | Outperform | Outperform |
2023-10-17 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-10-11 | Barclays | Upgrade | Equal-Weight | Equal-Weight |
2023-10-10 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-10-10 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-12 | BROADHURST VANESSA | Officer | 15.04K | Sale |
2024-02-12 | DECKER ROBERT J | Officer | 19.70K | Conversion of Exercise of derivative security |
2024-02-12 | DUATO JOAQUIN BOIX | Chief Executive Officer | 364.19K | Conversion of Exercise of derivative security |
2024-02-12 | FASOLO PETER M | Officer | 112.08K | Conversion of Exercise of derivative security |
2024-02-12 | FORMINARD ELIZABETH | General Counsel | 8.34K | Conversion of Exercise of derivative security |
2024-02-12 | HAIT WILLIAM | Officer | 38.65K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 247.48M | 40.96B | 9.52% |
2023-06-29 | Blackrock Inc. | 199.34M | 33.00B | 7.67% |
2023-06-29 | State Street Corporation | 141.83M | 23.48B | 5.46% |
2023-06-29 | Geode Capital Management, LLC | 49.70M | 8.23B | 1.91% |
2023-06-29 | Morgan Stanley | 41.67M | 6.90B | 1.60% |
2023-06-29 | JP Morgan Chase & Company | 31.78M | 5.26B | 1.22% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 81.05M | 13.42B | 3.12% |
2023-06-29 | Vanguard 500 Index Fund | 61.87M | 10.24B | 2.38% |
2023-05-30 | Fidelity 500 Index Fund | 29.26M | 4.54B | 1.13% |
2023-08-30 | SPDR S&P 500 ETF Trust | 26.52M | 4.29B | 1.02% |
2023-06-29 | Vanguard Index-Value Index Fund | 22.57M | 3.74B | 0.87% |
2023-08-30 | iShares Core S&P 500 ETF | 22.52M | 3.64B | 0.87% |
Dividend | Date |
---|---|
1.24 | 2024-05-20 |
1.19 | 2024-02-16 |
1.19 | 2023-11-20 |
1.19 | 2023-08-25 |
1.19 | 2023-05-22 |
1.13 | 2023-02-17 |
Split | Date |
---|---|
2 : 1 | 2001-06-13 |
2 : 1 | 1996-06-12 |
2 : 1 | 1992-06-10 |
2 : 1 | 1989-05-11 |
3 : 1 | 1981-05-19 |
3 : 1 | 1970-05-18 |
-
where is 150 damn
-
why is down
-
Pou Asus: what more info do u have about Janssen Coronavirus vaccine’s pioneering design. Ty.
-
How many knew that Ocugen had a partnership which contractually GUARANTEES them revenues from Covid19 Antibody Testing?
(re: page 22 of annual report):
https://www.sec.gov/Archives/edgar/data/1372299/000110465920053502/tm2017927-1_10ka.htm
Collaboration with Advaite, Inc.
In April 2020, the Company entered into an agreement with Advaite, Inc., (Advaite) to provide certain support services for Advaite's development of a diagnostic test kit that is designed to detect antibodies to COVID-19. ...{Ocugen}... will receive tiered royalty payments based on cumulative net sales of the test kit.The projected market for Covid diagnostic testing is $61B AND GROWING!
MORE IMPORTANTLY Advaite is NOW MOVING on Covid Antibody Testing!
https://www.linkedin.com/mwlite/company/advaite
*The BEAUTY here:
NOBODY KNOWS Ocugen will be collecting potentially BILLION$ in COVID DIAGNOSTICS revenue! They NEVER did a PRESS RELEASE! -
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
$SAVA - A second opinion
*
If you have been following $SAVA and their Alzheimers drug PTI-125, you will know that 1 of 2 endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, here is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, the Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT. That the efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
pepcid being tried for covid-19 distributed by jnj owned by bhc
-
Robinhood is giving away a free share in a company when you sign up. There is no monthly fees or commission fees. The share can range in price from $4.50 - $259. This is especially helpful for those who are now living from paycheck to paycheck and penny pinching. Take care everyone in these times.
-
Let’s buy more JJ
-
-
No Mr. Slayer as we
Have a very long term outlook unlike you. We are cheering the economy of our great country and are wishing that people like you disappear from this world so that American people can continue to keep their jobs. -
-
-
-
-
Yea that’s
-
The market missed it the judge declared 500 million for year one and said he didn’t have enough information going forward to determine monetary damages. Judge will revisit this monies will be much greater. Market will readjust tomorrow morning
-
That 500 million verdict was for year one. The market got it wrong. Judge said he didn’t have enough info for future years. Market will readjust tomorrow morning
-
-
(JNJ) Trading Advice
news.google.com • -
Johnson & Johnson Stock: Buy, Sell, or Hold?
fool.com • -
Johnson & Johnson Stock: Buy, Sell, or Hold?
news.google.com • -
Generational Wealth Builders: 3 Stocks to Own for Decades of Gains
investorplace.com • -
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
news.google.com • -
Are You Looking for a High-Growth Dividend Stock?
news.google.com • -
Are You Looking for a High-Growth Dividend Stock?
news.google.com • -
5 Stocks in Focus on Their Recent Dividend Hike
zacks.com • -
How Much Will $10k Invested in These Dividend Aristocrats Grow to by 2025?
investorplace.com • -
Johnson & Johnson (NYSE:JNJ) Shares Down 1.1%
news.google.com • -
3 Long-Term Stocks to Buy on the Dip: April 2024
news.google.com • -
Bert's March Dividend Income Summary
seekingalpha.com • -
Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.24
news.google.com • -
LLY vs. JNJ: Which Big Pharma Stock Is Better?- TipRanks
news.google.com • -
The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth
investorplace.com • -
Johnson and Johnson (JNJ) Elliott Wave technical analysis [Video]
news.google.com • -
4 Stocks to Watch on Their Recent Dividend Hikes
zacks.com • -
Johnson & Johnson: Legal Woes Are Detrimental But Not Fatal (NYSE:JNJ)
news.google.com • -
20 Years To $300k? Building A $10,000 Dividend Portfolio From Scratch
seekingalpha.com • -
Investing for the Long-Term: 3 Stocks With Proven Track Records
investorplace.com • -
Recession-Proof Riches: 3 Stocks That Thrive in Any Economy
investorplace.com • -
Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.
investorplace.com • -
Stocks on the move: UnitedHealth and Johnson & Johnson
youtube.com • -
Building Permits Come in Lower Than Expected
zacks.com • -
J&J's first quarter profits top estimates on strong cancer drug sales
proactiveinvestors.com • -
Johnson & Johnson Stock Slips After Mixed Q1 Earnings Report
investopedia.com • -
Johnson & Johnson is as Cheap as it's Going to Get
marketbeat.com • -
6 Dividend Aristocrats to Buy for Reliable Passive Income
247wallst.com • -
J&J CFO Joseph Wolk on Q1 earnings
youtube.com • -
Here's What To Expect From Johnson & Johnson's Q1
forbes.com • -
3 Blue Chip Stocks For Your April 2024 Watchlist
stockmarket.com • -
The 3 Best Stocks to Buy to Survive the Coming S&P 500 Crash
investorplace.com • -
3 Quarterly Releases to Watch Next Week
zacks.com • -
55 April Dividend Kings: Buy 8, Watch 8
seekingalpha.com • -
Johnson & Johnson: Doubling Down On This 2024 Dog Of The Dow
seekingalpha.com • -
Johnson & Johnson expected to face dip in first-quarter earnings
proactiveinvestors.com • -
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
investorplace.com • -
All-Time High Flyers: 7 Stocks to Buy as the Market Peaks
investorplace.com • -
Rallybio partners with J&J to advance therapies targeting rare fetal disease
proactiveinvestors.com • -
Wall Street Favorites: 3 Dividend Stocks With Strong Buy Ratings for April 2024
investorplace.com • -
7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape
investorplace.com • -
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
marketbeat.com • -
Johnson & Johnson to acquire medical device company Shockwave Medical for $13.1B
proactiveinvestors.com • -
Shockwave Medical Stock Rises After Johnson & Johnson Buyout
schaeffersresearch.com • -
SWAV Stock Alert: Shockwave Medical Lands Big Buyer in Johnson & Johnson
investorplace.com • -
Johnson & Johnson To Buy Shockwave Medical For $13.1 Billion
investors.com •